Menu
Menu
Our broad pipeline tackles a wide range of severe diseases in the therapeutic areas of oncology, the central nervous system (CNS), nephrology and immunology.
Oncology
Mutation agnostic KRAS-driven solid tumors
B-ALL, Burkitt’s, Double-HIT, DLBCL, Multiple Myeloma
CNS
Huntington’s Disease
Amyotrophic lateral sclerosis (ALS)
Alternative polyadenylation (APA)
Nephrology
High-risk genotypes for CKD
Focal segmental glomerulosclerosis (FSGS)
Immunology
Cell targeting for solid tumors
Cell and tissue-targeting for Th17-mediated diseases (i.g. – psoriasis, RA, MS, IBD, Chronic GvHD)
Our broad pipeline tackles a wide range of severe diseases in the therapeutic areas of oncology, the central nervous system (CNS), nephrology and immunology.
Oncology
Mutation agnostic KRAS-driven solid tumors
B-ALL, Burkitt’s, Double-HIT, DLBCL, Multiple Myeloma
CNS
Huntington’s Disease
Amyotrophic lateral sclerosis (ALS)
Alternative polyadenylation (APA)
Nephrology
High-risk genotypes for CKD
Focal segmental glomerulosclerosis (FSGS)
Immunology
Cell targeting for solid tumors
Cell and tissue-targeting for Th17-mediated diseases (i.g. – psoriasis, RA, MS, IBD, Chronic GvHD)
Our broad pipeline tackles a wide range of severe diseases in the therapeutic areas of oncology, the central nervous system (CNS), nephrology and immunology.
Oncology
Mutation agnostic KRAS-driven solid tumors
B-ALL, Burkitt’s, Double-HIT, DLBCL, Multiple Myeloma
CNS
Huntington’s Disease
Amyotrophic lateral sclerosis (ALS)
Alternative polyadenylation (APA)
Nephrology
High-risk genotypes for CKD
Focal segmental glomerulosclerosis (FSGS)
Immunology
Cell targeting for solid tumors
Cell and tissue-targeting for Th17-mediated diseases (i.g. – psoriasis, RA, MS, IBD, Chronic GvHD)
Our broad pipeline tackles a wide range of severe diseases in the therapeutic areas of oncology, the central nervous system (CNS), nephrology and immunology.
Mutation agnostic KRAS-driven solid tumors
B-ALL, Burkitt’s, Double-HIT, DLBCL, Multiple Myeloma
Huntington’s Disease
Amyotrophic lateral sclerosis (ALS)
Alternative polyadenylation (APA)
High-risk genotypes for CKD
Focal segmental glomerulosclerosis (FSGS)
Cell targeting for solid tumors
Cell and tissue-targeting for Th17-mediated diseases (i.g. – psoriasis, RA, MS, IBD, Chronic GvHD)